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carcinoma models
Clément Guillot1,2,5, Vincent Favaudon3,4, Zdenko Herceg5, Charlotte Sagne3,4,5, Sylvie Sauvaigo6, Philippe Merle1,2,7,
Janet Hall3,4 and Isabelle Chemin1,2*Abstract
Background: Hepatocellular carcinoma is the third cause of cancer related death for which new treatment
strategies are needed. Targeting DNA repair pathways to sensitize tumor cells to chemo- or radiotherapy is under
investigation for the treatment of several cancers with poly(ADP-ribose) polymerase (PARP) inhibitors showing great
potential. The aim of this preclinical study was to evaluate the expression of PARP and PARG genes in a panel of liver
cancer cell lines and primary human hepatocytes, their DNA repair capacity and assess the impact on cell survival
of PARP inhibitors alone and in combination with radiotherapy.
Methods: Quantitative PCR was used to measure PARP-1, −2, −3 and PARG mRNA levels and western blotting for
PARP-1 protein expression and ADP-ribose polymer formation after exposure of cells to doxorubicin, a topoisomerase II
poison. DNA repair capacity was assessed using an in vitro DNA lesion excision/synthesis assay and the effects on cell
killing of the PARP inhibitor ABT-888 alone and in combination with ionizing radiation using clonogenic survival.
Results: Although a wide range in expression of the PARPs and PARG was found correlations between PARP-1 and
PARP-2 mRNA levels and PARP-1 mRNA and protein levels were noted. However these expression profiles were not
predictive of PARP activity in the different cell lines that also showed variability in excision/synthesis repair capacity. 4 of
the 7 lines were sensitive to ABT-888 alone and the two lines tested showed enhanced radiosensitivity in the presence
of ABT-888.
Conclusions: PARP inhibitors combined with radiotherapy show potential as a therapeutic option for hepatocellular
carcinoma.
Keywords: Hepatocellular carcinoma, Poly(ADP-ribose) polymerases inhibitors, Radiation therapyBackground
Hepatocellular carcinoma (HCC) is the third cause of
cancer related death worldwide with an overall ratio of
mortality to incidence of 0.93 [1]. Due to the often late
diagnosis, possible curative therapies such as hepatic re-
section, liver transplantation and percutaneous ablation
can be offered to only a limited number of patients [2]
highlighting the need for the development of new treat-
ment strategies. Modern technologies have allowed the* Correspondence: isabelle.chemin@inserm.fr
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unless otherwise stated.emergence of new techniques in the field of radiation ther-
apy. For example, three-dimensional conformal radiother-
apy has the potential to accurately deliver high doses of
radiation within a well-defined HCC tumor volume while
sparing the surrounding non-tumor liver parenchyma and
the adjacent organs, therefore limiting radiation-induced
complications [3]. This method has shown promising
results with an 80% complete response for small-size
HCC nodules in patients non-eligible for standard cura-
tive therapies [4].
Molecules targeting DNA repair pathways have shown
great potential to sensitize tumor cells to both chemo-
and radiotherapy and increase their cytotoxicity [5]. In-
hibitors of poly(ADP-ribose) polymerases (PARPs) fallLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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several members of the PARP family, of which PARP-1
is the most prevalent. This ubiquitous post-translational
modification in mammalian cells modulates many cellular
responses including transcription, chromatin dynamics,
differentiation and cell death, in addition to playing a key
role in the response to DNA damage [6,7]. Once activated,
the PARP proteins catalyze the formation of ADP-ribose
polymers onto acceptor proteins. In addition to this direct
covalent modification, some proteins have a high affinity
for the polymers themselves and this is exploited in some
settings, for instance in DNA repair, for the control of the
localization and function of different repair proteins [8].
The radiosensitization effects of PARP inhibitors (PARPi)
have been shown to be specific to cells in the S-phase of
the cell cycle [9] and are due to the collision of the persist-
ing single strand breaks with replication forks and the for-
mation of a lethal DNA double strand break [10,11].
This cell cycle specificity of the impact of PARPi could
be of particular benefit in the treatment of cancer cells
that often show radioresistance during the S phase of
the cell cycle [12] and PARPi might result in increased
efficiency of radiotherapy in rapidly growing tumors with
a high S-phase content. Changes in the tumour micro-
environment brought about by PARPi can also have an
impact on responses to radiotherapy. For instance, vaso-
activity has been reported for some PARPi that may
modulate the levels of hypoxia within tumours [13,14].
Indeed, as hypoxic cells are more radioresistant than
oxic cells and intra-tumoural hypoxia can be a signifi-
cant source of treatment failure following radiotherapy,
the reoxygenation of hypoxic tumors could be of thera-
peutic benefit. Indeed, Liu et al. showed that inhibition
of PARP activity can sensitize hypoxic cancer cells and
the combination of ionizing radiation-PARP inhibition
has the potential to improve the therapeutic benefit of
radiotherapy [15]. Therefore, there is a strong rational
for the use of PARPi in association with radiation ther-
apy, in particular to counteract the radioresistance of
cancer cells in S phase and that of hypoxic cells.
PARPi have shown encouraging results in preclinical
trials as a single therapeutic agent in BRCA2 mutation
carriers of breast and ovarian cancers and also in com-
bination trials with chemotherapeutic agents and radio-
therapy [16]. Clinical trials of PARPi in combination with
radiation therapy are ongoing for instance, phase I and I/II
trials of veliparib (ABT-888) and olaparib in combination
with radiotherapy are ongoing for brain, lung, head and
neck, pancreas and breast cancers [17]. Recently, Quilez-
Perez and colleagues [18] have reported that the inhibition
of PARP activity using DPQ (3,4-dihydro-5-[4-(1-
piperidinyl)butoxyl]-1(2H)-isoquinolinone) was capable of
controlling HCC xenograft growth, protecting against
diethylnitrosamine-induced hepato-carcinogenesis andalso preventing tumour vasculogenesis by the transcrip-
tional regulation of both transcription factors and the
expression of genes involved in tumour progression.
Munoz-Gamez et al. [19] have shown that the PARPi
ANI (4-amino-1,8-naphthalimidecan) enhanced cell growth
inhibition induced by doxorubicin in human hepatoma cell
lines. Due to the strong rational of PARPi in combination
with radiation therapy and these promising effects of PARPi
on tumour growth in HCC models (reviewed in [20]), our
study was aimed to assess the potential of this combined
treatment strategy in a panel of eight liver cancer cell lines
and primary hepatocytes.
We first characterized the expression levels of several
of the PARP family members at the mRNA level, PARP-
1 protein levels and PARP activity. We then assessed dif-
ferences in repair capacities between cell lines using an
in vitro DNA repair assay and finally we evaluated the
cytotoxic potential of the PARPi ABT-888 as a single
agent treatment and in combination with ionizing radi-
ation in hepatoma cells.
Methods
Cell culture and drug treatment
HepG2 (ATCC HB-8065), HepG2 2.2.15 (kindly provided
by Prof. G. Acs, The Mount Sinai Medical Center, New
York, NY, USA), Huh7 (kindly provided by Dr. C. Seeger,
Fox Chase Cancer Center, Philadelphia, PA, USA), FOCUS
(kindly provided by Dr. J. R. Wands, Rhode Island Hos-
pital, Providence, RI, USA), Hep3B (ATCC HB-8064),
PLC-PRF-5 (ATCC CRL-8024) HCC cells and SKHep1
(ATCC HTB-52) adenocarcinoma cells were maintained in
DMEM/F-12 medium with 10% fetal bovine serum and
1% penicillin/streptomycin. Geneticin at 100 μg/ml was
added to the HepG2 2.2.15 cells’ medium. Primary human
hepatocytes (PHHs) were isolated from surgical liver speci-
mens obtained during partial hepatectomy. Informed con-
sent was obtained from each patient, and the procedure
was approved by the local Ethics Committee CPP Sud-Est
IV (Agreements of the French Ministry of Education and
Research n° AC-2013-1871 and n° DC-2013-1870, ISO
certification n° NFS 96 900). HepaRG hepatoma cells
(established in our laboratory, [21]) and PHHs were main-
tained in William’s E medium with 10% fetal bovine serum
and 1% penicillin/streptomycin supplemented with hydro-
cortisone sodium succinate. ABT-888 (Veliparib) (Abbott
Laboratories, Abbott Park, Illinois, USA) was dissolved in
ultrapure water and kept as a 4 mmol/L stock solution
in aliquots at −20°C. Doxorubicin (Caelyx) was kept as a
stock solution at 2 mg/ml in a pegylated liposomal for-
mulation at 4°C.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from three batches of each liver
cell line and PHHs by the RNAble (Eurobio, Courtaboeuf,
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was reverse-transcribed to cDNA. Real-time PCR was per-
formed with SYBRgreen technology using the KAPA SYBR
FAST qPCR kit (Clinisciences, Nanterre, France) following
the manufacturer’s protocol. All values were normalized for
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression levels. The relative quantification of gene ex-
pression was determined using the comparative Ct method.
All samples were assayed in triplicate, and mean expression
values were used. Primers (Table 1) were designed using
the PrimerQuest tool [22] using mRNA NCBI reference
sequences.
Western immunoblot analysis
Western blots of total cell extracts were carried out as pre-
viously described [11] using anti-PARP-1 C2-10 primary
antibody (BD Biosciences, Benelux, N.V) diluted 1: 1000
in TBS containing 5% milk, Tween-20 (TBS-MT) or anti-
pADPr 10H primary antibody (AbCAM, Paris, France) di-
luted 1 : 500 in TBS-MT.
Immunoblots were developed using the enhanced
chemiluminescence detection system (GE Healthcare life
sciences, Glattbrugg, Switzerland) following the manufac-
turer’s protocol and autoradiography. Semi-quantification
was made by densitometry analysis using Image J software
(NIH).
Genotyping of PARP-1 single nucleotide polymorphisms
rs8679 and rs1136410
The genotypes of the PARP-1 single nucleotide polymor-
phisms (SNPs) rs8679 and rs1136410 were determined
by direct sequencing of 10 ng genomic DNA (see Table 1
for primers and PCR conditions).Table 1 Primer pairs used for gene expression studies and se
studies
Primer name Primer sequence (5′-3′)
PARP-1 forward GCCGAGATCATCAGGAAGTATG
PARP-1 reverse ATTCGCCTTCACGCTCTATC
PARP-2 forward GTGGAGAAGGATGGTGAGAAAG
PARP-2 reverse CTCAAGATTCCCACCCAGTTAC
PARP-3 forward GAGACTACCAGCTTCTCAAGTG
PARP-3 reverse GTTGCTGCCAGTCTGTTCTA
PARG forward GTCACCGATGGATGTGGATAA
PARG reverse GGGAGGAACTACCATCTTCTTG
GAPDH forward CAAGAGCACAAGAGGAAGAGAG
GAPDH reverse CTACATGGCAACTGTGAGGAG
rs8679 forward TGTGGGAAGACCAAAGGAAG
rs8679 reverse ATAGAGAAGGCATCTGCATTTTTAAT
rs1136410 forward TTTGCCATTCACTGTGTTGG
rs1136410 reverse TTAATGTCAGTTTTGAGCTTCTCATAGClonogenic survival assays
Cells were diluted serially to appropriate concentrations
and seeded into 25 cm2 vented flasks at a cell density of
80 cells/cm2 in triplicate per data point and allowed to ad-
here for 4 h before treatment (37°C, 5% CO2). Cells were
then exposed or not to ABT-888 (10 μmol/L, 2 h) and
subsequently grown for 14 days, fixed in methanol and
stained with 0.05% Coomassie brilliant blue in 3:1:6 etha-
nol/acetic acid/water. Colonies larger than 50 cells were
counted by eye and the colony count relative to mock-
treated cells (Surviving fraction S) was determined. In
radiation survival assays, ABT-888 (10 μmol/L) was intro-
duced 1 h before irradiation. Irradiation was performed
using a Caesium-137 source (IBL-637 or a GSR D1) at
room temperature at a dose-rate of 0.012 Gy/s [11]. ABT-
888 was removed 1 h after irradiation. The colony count
relative to mock-treated cells (S) was adjusted for best fit
to the classical linear-quadratic equation (Ln S = − α.D - β.
D2) where D is the radiation dose and α and β adjustable
parameters characterizing the radiosensitivity. The mean
lethal dose (D37), i.e., the dose of radiation leaving 1/e =
0.37 survival, was calculated from the α, β values. Calcula-
tions were made through nonlinear least-squares regres-
sion taking all data points into account, using Kaleidagraph
software (Synergy Software, Reading, Pennsylvania).
DNA excision/synthesis assay
Cells (3.106 cells) were pelleted by centrifugation and sus-
pended in DMEM/F-12 medium completed with 10% fetal
bovine serum and 10% DMSO and frozen at -80°C until
the preparation of cell extracts. Cell nuclear extracts were
prepared as previously described [23]. Protein content was
in the 1–3 mg/mL range. For the plasmid microarrayquencing for single nucleotide polymorphisms genotype
Tm (°C) NCBI reference sequence
62 [GenBank:NM_001618.3]
62
62 [GenBank:NM_001042618.1]
62
62 [Genbank:NM_001003931.2]
62
62 [GenBank:NM_003631.2]
62
62 [GenBank:NM_001256799.1]
62
52
52
55
55
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(Woodbridge, CT, USA). Six types of DNA lesions were
generated in the plasmids before their spotting: photoprod-
ucts (cyclobutane pyrimidine dimers and (6–4) photoprod-
ucts; CPD-64 plasmid), 8-oxoguanine (8oxoG plasmid),
alkylated bases (AlkB plasmid), T-T inter- and intra-strand
crosslinks psoralen adducts (Pso plasmid), abasic sites (AP
sites; AbaS plasmid) and cytosine and thymine glycols (Gly-
col plasmid). Each type of modified plasmid was then di-
luted in non-modified plasmid so we obtained 3 solutions
of identical DNA concentration (40 μg/mL) but with 3 dif-
ferent ratios of lesion/DNA (ratios ½, ¾ and 1). On all mi-
croarrays each plasmid solution was spotted in duplicate
except the control that was deposited 9 times. Excision/syn-
thesis reaction was conducted on the modified plasmid ar-
rays as described in [24] at a final protein concentration of
0.2 mg/mL for all samples. Each extract was tested in dupli-
cate. Images were acquired by scanning the support at
532 nm at a 10 μm resolution using an InnoScan710AL
scanner (Innopsys, France). Total spot fluorescence inten-
sity was determined using the Mapix software (Innopsys).
Duplicate data were normalized using NormalizeIt software
[23]. Each sample was characterised by 6 fluorescence in-
tensity values corresponding to the repair of the 6 DNA le-
sions represented on the biochip.
Statistical analysis
For gene and protein expression analyzes we applied a
base-10 logarithmic transformation to the values. Data
are expressed as means ± standard error of mean (SEM).
P values were calculated by independent t-test between
two groups using GraphPadPrism4 software (GraphPad,
La Jolla, CA, USA) *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Correlation analyzes were made by Pearson test. For
total fluorescence intensity of excision/synthesis assays,
we applied a base-10 logarithmic transformation to the
values. Data are expressed as means ± standard deviation
(SD). P values were calculated by independent t-test be-
tween two groups.
Results
mRNA expression of PARP-1, PARP-2, PARP-3 and PARG in
liver cells
Before analyzing the cell killing effects of a PARPi and ion-
izing radiation, we investigated the expression of three
members of the PARP family and poly(ADP-ribose) glyco-
hydrolase (PARG) and PARP enzymatic activity profiles in
a panel of liver cancer cell lines and PHHs: HepG2, Huh7,
FOCUS are hepatoma cell lines, SKHep1 an adenocarcin-
oma cell line, HepaRG a non-tumorigenic hepatoma cell
line and HepG2 2.2.15 is a clone of HepG2 cells harboring
in its genome four tandem copies of the hepatitis B virus
(HBV) genome. Hep3B is a hepatoma cell line containing
a naturally integrated HBV genome and PLC-PRF-5 is ahepatoma cell line expressing HBV surface antigen
(HBsAg). Some considerable variation in the mRNA ex-
pression levels was seen within the panel of cell lines
examined compared to the PHHs (Figure 1A). We found
a significant correlation between PARP-1 and PARP-2
mRNA expression (Pearson correlation coefficient r =
0.8482, two-tailed p value = 0.0039, Figure 1B); however
no correlation was found between the expression of the
other genes at the mRNA level.
PARP-1 protein expression and PARP activity in liver cells
To test whether the mRNA expression correlates with
protein levels, we next measured PARP-1 protein levels
in the same panel using western blot analysis (Figure 2A).
Densitometry analyses were performed on three inde-
pendent experiments (Figure 2B) and a significant posi-
tive correlation was found between PARP-1 protein and
mRNA expression (Pearson correlation coefficient r =
0.6840, one-tailed p value = 0.0252, Figure 2C). It was
noted that the HepG2 2.2.15 and Hep3B cells, that both
carry an integrated HBV genome in their own genome,
exhibited the highest expression levels and PLC-PRF-5
cells which express the viral antigen HBsAg also have
high PARP-1 protein levels. Almost all liver cancer cell
lines have a higher PARP-1 protein expression than that
observed in PHHs. Differences in PARP activity between
the eight liver cell lines were measured by treating the
cells with doxorubicin for 2 h to induce ADP-ribose
polymers (pADPr) synthesis and analyzing the pADPr
generated by western blot (Figure 2D). As has already
been reported in other systems [25], PARP activity did
not reflect PARP-1 expression profiles, and we did not
find any correlation between PARP activity and either
PARP-1 protein or mRNA levels. The PARP-1 Val762Ala
(T2444C) rs1136410 SNP has been associated with a re-
duced ADP-ribosylation activity and cancer susceptibility
[26,27] and the PARP-1 3′ UTR rs8679 T > C SNP is as-
sociated with bladder and breast cancer risk [28]. All the
cell lines were homozygous for the T allele of both SNPs
except HepG2 and HepG2 2.2.15 that were heterozygous
for both (Table 2). No consistent differences in PARP-1
mRNA or protein expression and PARP activity were
noted between these two lines and the others.
Liver cancer cells have different sensitivity to ABT-888
given as a single agent treatment
To verify the effective inhibition of PARP activity by ABT-
888 in liver cells HepG2 cells were treated for 2 h with
doxorubicin to induce pADPr synthesis in the presence or
absence of 10 μM ABT-888 and pADPr formation analyzed
by western blot. No pADPr was detected in cells co-treated
with ABT-888 and doxorubicin, showing that under these
conditions PARP activity was inhibited (Figure 3A). We
then analyzed the effect of ABT-888 as a single agent
Figure 1 PARP-1, PARP-2, PARP-3, PARG genes expression in liver cancer cell lines and primary human hepatocytes. (A) Gene expression
profiles were analyzed by real-time quantitative PCR, expressed as % of GAPDH expression. (B) Pearson correlation analysis showed a significant
positive correlation of PARP-1 vs. PARP-2 gene expression (Pearson correlation coefficient r = 0.8482 , two-tailed p value = 0.0039).
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cell lines in our test panel (Figure 3B). Of these cells,
FOCUS, HepG2 2.2.15 and HepG2 were sensitive to the
cell killing effects of ABT-888 alone whilst Hep3B and
Huh7 cells showed a lower sensitivity. Based on the obser-
vations and the PARP activity measured we selected the
HepG2 (intermediate PARP activity and sensitive to ABT-
888) and PLC-PRF-5 (low PARP activity and resistant to
ABT-888) cell lines for the further experiments combining
radiation exposure with ABT-888 treatment.
Liver cancer cells have different excision/synthesis DNA
repair capacity
The PARP proteins are involved in several DNA repair
pathways and thus PARP inhibition could impact on the
repair of different DNA lesions. In order to evaluate the
constitutive inter-line variation in repair capacity we
used a novel excision/synthesis repair assay that makes
use of a microarray on which plasmids are spotted that
contain different types of DNA damage: CPD and 6-4PPs, Pso lesions that are typically repaired by nucleo-
tide excision repair; 8oxoG, AlkB, AbaS and glycol le-
sions that are typically repaired by the base excision
repair pathway. We first analyzed the total excision/
synthesis capacities of each cell line by assessing the
total fluorescence values for all the “damaged” plasmids.
Using this endpoint, we observed that FOCUS had the
highest levels of overall repair capacity, with HepG2,
Huh7 and HepG2 2.2.15 cells having intermediate
capacities. Conversely, PLC-PRF-5 had a significantly
lower capacity compared to the other cells examined
(Figure 4A). All the cell lines presented a similar profile
of excision/synthesis repair for the different DNA lesion
types assessed with a high capacity to repair 8oxoG and
glycol modified bases, a lower capacity for AlkB, CPD
and 6-4PPs and lower capacities for the repair of AbaS
and the lowest seen for Pso lesions (Figure 4B). The low
capacity of PLC-PRF-5 cells to repair DNA damage as
assessed by this excision/synthesis assay is intriguing in
the light of the apparent resistance to the cell killing
Figure 2 PARP-1 protein expression and PARP activity in liver cells. (A) PARP-1 protein expression was analyzed by western blotting.
(B) Densitometry analyses of PARP-1 expression were performed on three independent western blotting experiments. (C) Pearson correlation
analysis was performed on the mean of gene and protein expression values and showed a significant positive correlation of PARP-1 protein
vs. PARP-1 mRNA expression (Pearson correlation coefficient r = 0.6840, one-tailed p value = 0.0252). (D) PARP activity was measured by western
blot analysis of pADPr after cells were treated with 5 μg/ml doxorubicin. HepG2 cells non-treated with doxorubicin were used as a control.
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ABT-888 as a single agent described above.ABT-888 sensitizes liver cancer cells to the cell killing
effects of ionizing radiation
In order to assess the potential of ABT-888 as a radio-
sensitizer in liver cancer cells we treated HepG2 and
PLC-PRF-5 cells with ABT-888 for 2 h and exposed cells
to ionizing radiation 1 h after the addition of the PARPi
and analyzed cell survival in a clonogenic assay. ABT-
888 sensitized both cell lines to the cell killing effects of
ionizing radiation . Based on the ratio of the D37 values
ABT-888 enhanced the radiation susceptibility of HepG2Table 2 Genotypes of PARP-1 single nucleotide
polymorphisms rs1136410 and rs8679 in liver cancer cell
lines
Cell line rs1136410 genotype rs8679 genotype
HepG2 T/C T/C
HepG2 2.2.15 T/C T/C
Huh7 T/T T/T
FOCUS T/T T/T
SKHep1 T/T T/T
HepaRG T/T T/T
Hep3B T/T T/T
PLC-PRF-5 T/T T/Tand PLC-PRF-5 cells by 1.48 ± 0.22 and 1.17 ± 0.36, re-
spectively (Figure 3C).
Discussion
Hepatocellular carcinoma is one of the most severe can-
cers worldwide and curative treatments can be offered to a
limited number of patients. In this study, we investigated
the potential of PARPi to sensitize liver cancer cells to ion-
izing radiation. Knowing that PARP-1 mRNA levels are
up-regulated in several cancer types [29], we compared the
mRNA expression profiles of PARP-1, PARP-2 , PARP-3
and PARG in eight liver cancer cell lines to that of PHHs.
PARP-1 and PARP-2 mRNA expression appear to be up-
regulated in most of the liver cancer cell lines studied in
comparison with PHHs although not all the differences in
expression were significant. The expression of PARP-1
mRNA correlated well with the PARP-2 mRNA expres-
sion. This similar expression profile could reflect shared
functions in the base excision pathway [6]. In contrast,
PARP-3 mRNA was down-regulated in cancer cells com-
pared to normal cells. Only two cell lines showed signifi-
cant PARP-3 up-regulation. Interestingly, Rouleau and
colleagues [30] showed in the Cynomolgus monkey that
PARP-3 protein is not expressed in hepatocytes and its
expression is restricted to bile ducts cells. PARG mRNA
levels are only significantly higher in two cancer cell lines.
These expression profiles are consistent with what it was
already observed in breast tumors [31]. Recently, Ko and
colleagues [32] have shown that PARPi can enhance HBV
replication and we found high levels of PARP-1 mRNA
Figure 3 Effect of the ABT-888 treatment and/or radiation treatment in liver cancer cell lines. (A) Inhibition of PARP activity was measured
by western blot analysis of pADPr levels after HepG2 cells were treated with 5 μg/ml doxorubicin and/or 10 μM ABT-888 for 2 h. Control treatment
was the solvent of ABT-888. (B) Effect of ABT-888 on clonogenic survival of liver cancer cell lines. Cells were treated with 10 μM ABT-888 for 2 h and
allowed to grow for 14 days after treatment. (C) Radiation survival of HepG2 (two independent experiments, each in triplicate) and PLC-PRF-5
cells (one experiment in triplicate) without (open symbols) or with (full symbols) ABT-888. The curves were drawn for best fit to the linear-quadratic
equation (see Methods). To determine whether the drug-induced modification of radiation response was significant or not, a non-parametric
Mann–Whitney U-test was performed on paired sets of data. **, p < 0.001; ***, p < 0.0001 using StatEL (AD Science, Paris, France).
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tegrated HBV genome (although HepG2 2.2.15 cells origi-
nated from HepG2 cells and both express similar levels of
the PARP-1 gene and protein). These observations would
suggest that particular attention needs to be given to pa-
tients who are infected with HBV and are on clinical trials
involving PARPi, and it needs to be established whether
PARPi can enhance HBV replication in such patients. Sev-
eral studies have examined whether correlations exist be-
tween PARP-1 mRNA levels, protein levels and PARP
enzymatic activity. In the panel of liver cells examined we
found a correlation between mRNA and protein expres-
sion which is generally not a common feature for instance
in breast tumors [31] but not between protein expression
and PARP activity as has already been observed [25]. No
correlation was found between the rs1136410 and rs8679
genotypes and PARP-1 expression and PARP activity al-
though only 2 lines carried the variant alleles of these
two SNPs which limited the possibility to detect any such
genotype specific differences in activity or expression.
The presence of PARP-1 at the protein level in liver can-
cer cells and detected poly(ADP-ribosyl)ation activity
allowed us to investigate the effects of PARPi in these cell
lines. Interestingly, the different liver cancer cell lines ana-
lyzed showed differential sensitivity to the PARPi ABT-888used as a single agent treatment. Zhang et al. [33] have
also observed liver cell lines with differential sensitivity to
the PARPi olaparib. In a first attempt to investigate the
underlying reasons for this differential sensitivity we
assessed the overall capacity of the cells to carry out the
excision/synthesis step for a number of different DNA le-
sions that are repaired via the base excision repair and nu-
cleotide excision repair pathways. Using this assay we
found that the cell lines had some considerable variation
in repair capacity for the different lesions with the PLC-
PRF-5 cells having very low capacity. This result would
suggest that the apparent resistance to the cell killing ef-
fects of ABT-888 seen in the clonogenic survival assays
may originate from the over-expression of repair activities
such as DNA double strand break repair that cannot be
assessed using this in vitro assay.
Based on these profiles, we selected one cell line sensi-
tive to the cell killing effects of ABT-888 used as a single
agent treatment and having high levels of PARP activity
and one cell line resistant to ABT-888 under these con-
ditions with low levels of PARP activity to compare their
response to the combination of ABT-888 and ionizing
radiation. Based on the D37 values the radiation suscepti-
bility of HepG2 cells was 2.3-fold higher than that of
PLC-PRF-5 cells in the absence of ABT-888. The PARPi
Figure 4 Excision/synthesis abilities of liver cancer cells. (A) Total excision/synthesis abilities were analyzed using damaged plasmids
microarray containing six DNA damage types and by adding total fluorescence intensity of all DNA lesions. (B) Excision/synthesis abilities for each
type of DNA lesion (cyclobutane pyrimidine dimers and 6–4 photoproducts (CPD-64), T-T inter- and intra-strand crosslinks psoralen adducts (Pso),
8-oxoguanine (8oxoG), alkylated bases (AlkB), abasic sites (AbaS) and cytosine and thymine glycols (glycol).
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higher in HepG2 (1.48 ± 0.22) than in PLC-PRF-5 cells
(1.17 ± 0.36). These different responses could reflect the
differential sensitivity of the two cell lines to ABT-888.
PARPi were initially shown to be cytotoxic for cells lack-
ing a component of homologous recombination pathway
(reviewed in [8]). Further investigations into the genetic
background of sensitive and resistant cells will be needed
to provide a better understanding of the different re-
sponses to the combination of PARPi with ionizing ra-
diation. Our results suggest that the response to thiscombination treatment might depend on cells’ capacities
to repair DNA damage and assessing DNA repair cap-
acities of tumor cells from patients undergoing clinical
trials of PARPi could help to adjust radiation therapy
schedules.
Conclusions
Altogether, our results confirmed the strong potential of
PARPi to enhance ionizing radiation in liver cancer cells
letting us consider preclinical mice studies and clinical
trials of such combination treatment.
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